Short Interest in Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Rises By 320.0%

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the recipient of a significant increase in short interest in June. As of June 30th, there was short interest totaling 94,847 shares, an increase of 320.0% from the June 15th total of 22,583 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 483,454 shares, the short-interest ratio is presently 0.2 days.

Oncotelic Therapeutics Price Performance

Shares of OTLC traded down $0.00 during trading hours on Monday, reaching $0.04. 618,459 shares of the stock traded hands, compared to its average volume of 291,897. The company has a market cap of $16.40 million, a P/E ratio of 0.06 and a beta of -0.27. The company has a current ratio of 0.11, a quick ratio of 0.11 and a debt-to-equity ratio of 0.01. The company’s 50-day moving average price is $0.05 and its two-hundred day moving average price is $0.05. Oncotelic Therapeutics has a 52-week low of $0.01 and a 52-week high of $0.11.

Oncotelic Therapeutics (OTCMKTS:OTLC) last issued its quarterly earnings results on Wednesday, April 15th. The company reported $0.59 earnings per share (EPS) for the quarter.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.

Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.